Wave Life Sciences (WVE) Is Down 11.4% After Positive WVE-006 AATD Data and Accelerated Path Update
Wave Life Sciences (WVE) stock dropped 11.4% despite reporting positive Phase 1b/2a data for its RNA editing candidate WVE-006 for alpha-1 antitrypsin deficiency (AATD). The data showed WVE-006 reduced harmful Z-AAT and restored protective M-AAT with convenient subcutaneous dosing and a favorable safety profile, and the company expects regulatory feedback on a potential accelerated approval path by mid-2026. However, investors remain concerned about widening losses, reliance on a few programs, and potential future dilutive funding, even after a recent US$350 million equity offering in late 2025 extended their cash runway into 2027.
Wave Life Sciences Is Maintained at Overweight by Wells Fargo
Wells Fargo has reaffirmed its "Overweight" rating for Wave Life Sciences. The report does not provide further details on the reasons for maintaining this rating.
WVE: Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum
Wave Life Sciences (WVE) is making significant progress in its siRNA and RNA editing platforms, demonstrating promising clinical data for obesity and AATD. The company is pursuing monthly dosing regimens and biomarker-driven regulatory strategies. New studies will focus on high BMI and cardiometabolic endpoints, as highlighted in their recent RBC Capital Markets Global Healthcare Conference.
Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says
Wedbush reiterated its Outperform rating and $16 price target on Wave Life Sciences following the announcement of new data from its Phase 1b/2a clinical trial for WVE-006 in alpha-1 antitrypsin deficiency (AATD). The analyst noted that the initial data met expectations, showing dose-dependent reductions in serum alpha-1 antitrypsin (AAT) and mutant alpha-1 antitrypsin (Z-AAT) protein. The study's early success suggests a promising path for WVE-006, positioning Wave Life Sciences positively in the AATD treatment landscape.
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
Wave Life Sciences has announced its support as an inaugural industry sponsor for AlphaDetect, a nonprofit organization powered by the Alpha-1 Foundation. This partnership aims to enhance the routine detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in patients with liver and/or lung disease by providing free genetic testing and support for healthcare providers. The collaboration seeks to address the significant underdiagnosis of Alpha-1 and connect affected individuals with essential care, resources, and research.
Free genetic tests try to catch Alpha-1, a hidden COPD risk
Wave Life Sciences (NASDAQ: WVE) has become an inaugural industry sponsor of AlphaDetect, a nonprofit organization powered by the Alpha-1 Foundation, to accelerate the detection of Alpha-1 Antitrypsin Deficiency (Alpha-1). This partnership will provide free genetic testing and support for healthcare providers to address the significant underdiagnosis of Alpha-1, a genetic condition and leading risk factor for COPD and liver disease. The collaboration aims to scale proven detection strategies and improve access to care and resources for affected individuals.
Cantor Fitzgerald reiterates Overweight on Wave Life Sciences stock
Cantor Fitzgerald has reiterated an Overweight rating and a $13.00 price target for Wave Life Sciences (NASDAQ:WVE), citing new clinical data for its WVE-006 program. The WVE-006 program, an RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, has shown consistent editing and M-AAT production across all patient cohorts. The firm views WVE-006 as the most advanced RNA editing program at a pivotal stage, anticipating manageable clinical and regulatory risk if FDA feedback for an accelerated approval pathway is positive.
Wave Life Sciences stock price target lowered to $13 by H.C. Wainwright
H.C. Wainwright has lowered its price target for Wave Life Sciences (NASDAQ:WVE) to $13 from $18, while maintaining a Buy rating. The adjustment follows the company's WVE-006 ATS 2026 readout, which showed lower total AAT levels compared to competitors and suggested a saturated dose-response curve. Despite this, InvestingPro analysis indicates the stock may still be undervalued, and six analysts have revised earnings upwards for the upcoming period.
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Wave Life Sciences announced positive updated data from its RestorAATion-2 trial for WVE-006, an investigational RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD). The data indicate that WVE-006 achieves an MZ-like phenotype, effectively reducing harmful Z-AAT protein and restoring wild-type M-AAT dynamically, addressing both lung and liver manifestations of AATD with a favorable safety profile and convenient dosing. The company expects regulatory feedback on a potential accelerated approval pathway mid-2026.
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call - Slideshow (NASDAQ:WVE) 2026-05-18
Wave Life Sciences Ltd. published a slide deck for a shareholder/analyst call related to its stock (WVE). The article from SA Transcripts highlights the release of this slide deck, providing insights for investors and analysts interested in the company's performance and future outlook.
Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing
Wave Life Sciences (WVE) announced positive results from its RestorAATion-2 study, demonstrating that WVE-006 effectively restores protective M-AAT and significantly reduces harmful Z-AAT. The drug showed durable RNA editing effects and was well-tolerated, with both biweekly and monthly dosing regimens proving effective. Wave expects FDA feedback on an accelerated approval pathway by mid-2026 and will release additional data later that year.
WVE-006 AATD trial shows strong biomarker gains for Wave Life Sciences (WVE)
Wave Life Sciences (WVE) announced positive updated data from its RestorAATion-2 Phase 1b/2a trial of WVE-006 for alpha-1 antitrypsin deficiency (AATD). The subcutaneous RNA editing therapy demonstrated significant reductions in harmful Z-AAT protein and restoration of protective M-AAT to levels observed in low-risk MZ individuals, alongside a favorable safety profile. The company anticipates FDA feedback on an accelerated approval pathway by mid-2026.
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Wave Life Sciences announced positive interim results from its RestorAATion-2 trial for WVE-006, an investigational RNA editing therapy for alpha-1 antitrypsin deficiency (AATD). The data showed that WVE-006 achieved an MZ-like phenotype, producing healthy M-AAT and reducing harmful Z-AAT across both biweekly and monthly dosing, with sustained effects and a favorable safety profile. The company expects to engage with the FDA on a potential accelerated approval pathway by mid-2026 and will share more data in the second half of the year.
Experimental RNA-editing shot aims to treat lung and liver damage in alpha-1
Wave Life Sciences announced positive updated Phase 1b/2a data for WVE-006, an investigational RNA editing oligonucleotide, for alpha-1 antitrypsin deficiency (AATD). The drug demonstrated significant reductions in harmful Z-AAT protein and restoration of protective M-AAT protein, achieving levels comparable to those in individuals with a low risk of AATD-related disease, with both biweekly and monthly dosing. The study also highlighted WVE-006's favorable safety profile and its ability to restore dynamic AAT production, with regulatory feedback on an accelerated approval pathway expected mid-2026.
WVE: WVE-006 achieved up to 71% Z-AAT reduction and restored protective M-AAT levels in AATD
Wave Life Sciences' WVE-006, an RNA editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), showed promising results in the RestorAATion-2 study. The therapy achieved up to a 71% reduction in mutant Z-AAT and restored protective M-AAT levels. This indicates robust safety and efficacy, supporting a monthly dosing regimen due to durable editing and dynamic AAT response.
Wedbush Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15
Wedbush has reiterated its Buy rating for Wave Life Sciences (WVE.US) and maintained its price target at $15. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says
Wedbush analysts believe that new data from Wave Life Sciences' ATS (allele-selective silencing) programs could validate the company's RNA editing platform. This validation would have significant implications, potentially leading to the use of their RNA editing approach in a broader range of therapeutic areas beyond the current focus. The analysts also see a clear path to drug development beyond the initial programs.
Wave Life Sciences stock (SG1V20936237): Starts Phase 1 trial for one-time GLP-1 gene therapy
Wave Life Sciences has initiated a Phase 1 human trial for its GLP-1 gene therapy, targeting obesity treatment with a focus on weight reduction and muscle preservation through infrequent dosing. This development represents a significant step in RNA-based therapeutics, utilizing the company's PRISM platform to address both rare and prevalent diseases. The Nasdaq-listed stock (WVE) is positioned in a growing biotechnology sector, offering US investors access to innovative solutions for areas with high unmet medical needs.
Wave Life Sciences (WVE) price target decreased by 15.26% to 23.97
The price target for Wave Life Sciences (WVE) has been decreased by 15.26% to $23.97. This adjustment reflects a revised outlook or valuation for the company's stock. Investors and analysts will likely be reviewing the factors contributing to this change.
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Wave Life Sciences Ltd. (Nasdaq: WVE) announced that its President and CEO, Paul Bolno, MD, MBA, is scheduled to participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 8:00 a.m. ET. A live webcast and subsequent replay will be available on the Investors section of the company's website. The company is a clinical-stage biotechnology firm focusing on RNA medicines for various disorders.
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Wave Life Sciences (Nasdaq: WVE) announced that its President and CEO, Paul Bolno, MD, MBA, will participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026. The clinical-stage biotechnology company focuses on RNA medicines for rare and common disorders, with a pipeline including programs for obesity, alpha-1 antitrypsin deficiency, and PNPLA3 I148M liver disease. Bolno's presentation will be webcast live and archived on the company's investor relations website.
Wave Life Sciences CEO to join RBC healthcare conference fireside chat
Wave Life Sciences (Nasdaq: WVE) announced that its President and CEO, Paul Bolno, will participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026. The company, focused on RNA medicines, will provide a live webcast and replay of the presentation. This announcement follows recent updates on the company's Q1 2026 financial results, a proposed redomiciliation, and positive interim Phase 1 clinical data for WVE-007.
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Wave Life Sciences Ltd. announced that its President and CEO, Paul Bolno, MD, MBA, is scheduled to participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 8:00 a.m. ET. A live webcast and replay of the presentation will be available on the Investors section of the company's website. The company, focused on RNA medicines, highlighted its PRISM® platform and pipeline for various disorders.
Adage (NASDAQ: WVE) discloses 1,000,000-share stake, 0.53% of class
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a shared beneficial ownership of 1,000,000 Ordinary Shares in Wave Life Sciences Ltd. (WVE), representing 0.53% of the class. This information was filed via a Schedule 13G/A, a routine update for passive investments. The percentage is calculated based on 188,254,954 Ordinary Shares outstanding as of February 19, 2026.
Surging Q1 Revenue And Narrower Losses Might Change The Case For Investing In Wave (WVE)
Wave Life Sciences Ltd. (WVE) reported a significant increase in first-quarter 2026 revenue to US$38.25 million, up from US$9.18 million, alongside a narrower net loss of US$26.09 million. This improved financial performance, especially the quadrupling of year-over-year revenue, could positively impact the company's investment narrative by reducing immediate funding pressure. While a key clinical catalyst involves moving WVE-007 into Phase 2a for obesity, investors should still consider liquidity risks and reliance on unpredictable partnership revenue.
Surging Q1 Revenue And Narrower Losses Might Change The Case For Investing In Wave (WVE)
Wave Life Sciences (WVE) reported a significant increase in Q1 2026 revenue to US$38.25 million, up from US$9.18 million, and a narrowing net loss to US$26.09 million. This improved financial performance, particularly the quadrupled revenue, is seen as buying Wave Life Sciences more time for its clinical programs, especially WVE-007 for obesity, reducing immediate funding pressure. However, ongoing risks related to unproven late-stage clinical outcomes and reliance on unpredictable partnership revenue remain.
Wave Life Sciences (NASDAQ: WVE) seeks shareholder approval for Delaware move
Wave Life Sciences (NASDAQ: WVE) is seeking shareholder approval to redomicile its parent company from Singapore to Delaware through a Scheme of Arrangement. The company believes this move will better align its legal framework with its U.S.-focused operations and shareholder base, and reduce administrative costs. Shareholders will exchange their Wave-Singapore shares one-for-one for Wave-Delaware common stock, which will continue to trade on Nasdaq under the symbol “WVE”.
Wave Life Sciences: Good Platform, Mixed Clinical Trial Data, Hold. (NASDAQ:WVE)
Wave Life Sciences, a clinical-stage biotechnology firm, is leveraging its PRISM platform to develop stereopure oligonucleotide therapeutics, with WVE-006 for AATD and WVE-007 for weight loss as key near-term drivers. While WVE-006 trails BEAM-302 in efficacy, its cleaner safety profile and upcoming 2026 data could narrow the gap. The company holds a strong cash position of $602M, funding operations until Q3 2028, and its valuation upside relies on FDA validation of RNA editing technology, potentially reaching $5.1B compared to its current ~$1.4B market cap, though significant clinical trial risks remain.
Surging Q1 Revenue And Narrower Losses Might Change The Case For Investing In Wave (WVE)
Wave Life Sciences Ltd. reported a significant increase in Q1 2026 revenue to US$38.25 million from US$9.18 million year-over-year, alongside a narrower net loss of US$26.09 million. This improved financial performance, particularly the quadrupling of revenue, suggests more efficient operations and helps alleviate short-term funding concerns for the company, supporting its investment narrative focused on its RNA platform and clinical programs like WVE-007. The positive results might lead analysts to re-evaluate Wave's future funding risk and clinical payoffs.
FMR LLC takes 2.8% position in Wave Life Sciences (NASDAQ: WVE)
FMR LLC has reported a 2.8% stake in Wave Life Sciences (NASDAQ: WVE), beneficially owning 5,192,761.43 shares of common stock as of March 31, 2026. The Schedule 13G/A filing indicates that FMR LLC holds sole voting power over 5,189,539 shares and sole dispositive power over all 5,192,761.43 shares, with Abigail P. Johnson also having dispositive power. This filing is a passive investment disclosure and does not signal any intent to change or influence control of the issuer.
Wave Life Sciences (NASDAQ: WVE) proposes one‑for‑one redomiciliation to Delaware
Wave Life Sciences (WVE) is proposing to redomicile its parent company from Singapore to Delaware through a Scheme of Arrangement. This one-for-one exchange of Singaporean ordinary shares for Delaware common stock aims to streamline corporate structure, reduce administrative costs, and align with its U.S.-focused operations and substantial U.S. shareholder base. The plan requires shareholder and Singapore Court approval and is intended to be a tax-free reorganization for U.S. federal income tax purposes.
Pictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVE
Pictet Asset Management Holding SA significantly increased its stake in WAVE Life Sciences Ltd. by 5,024.6%, acquiring 790,175 additional shares to hold a total of 805,901 shares valued at $13.83 million. Other major institutional investors like Federated Hermes, Adage, Vanguard, and Two Sigma also increased their positions, resulting in institutional ownership of approximately 89.73% of WVE stock. This news follows WAVE Life Sciences' strong quarterly earnings report, where the company surpassed revenue and EPS expectations.
A Look At Wave Life Sciences (WVE) Valuation After Q1 2026 Results And RNA Pipeline Progress
Wave Life Sciences (WVE) reported Q1 2026 results with $38.25 million in sales and a net loss of $26.09 million, alongside advancements in its RNA clinical programs. Despite a recent share price decline, analysts project a fair value of $34.06, citing future RNA pipeline progress and potential revenue expansion, though wider losses and dependence on milestone payments present risks. The company's current P/S ratio of 19.6x is significantly higher than the industry average, indicating potential valuation risk.
A Look At Wave Life Sciences (WVE) Valuation After Q1 2026 Results And RNA Pipeline Progress
Wave Life Sciences (WVE) reported Q1 2026 sales of US$38.25 million and a net loss of US$26.09 million, with notable progress in its RNA pipeline. Despite a recent 7.17% share price return, it follows a 43.43% decline over three months, yet longer-term holders still show an 83.46% three-year return. Analysts project a fair value of $34.06, considering future pipeline developments, while the current P/S ratio of 19.6x suggests a significant valuation risk compared to the industry average.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts
WAVE Life Sciences Ltd. (NASDAQ:WVE) has received a "Moderate Buy" consensus rating from analysts, with 14 buy recommendations and one sell recommendation, and an average 1-year price target of $27.88 despite recent target trims by some firms. The company recently beat earnings estimates, reporting EPS of ($0.13) against expectations of ($0.34) and significantly higher revenue, though it still has negative margins. While insiders have been selling shares, institutional investors and hedge funds, including GSK and Price T. Rowe, have significantly increased their ownership, now holding approximately 89.7% of the stock.
Wave Life Sciences (Nasdaq: WVE) details 2025 milestones, cash and executive pay
Wave Life Sciences (WVE) filed an amendment to its 10-K report, providing detailed information on its directors, executive officers, corporate governance, and executive compensation for 2025. The company highlighted significant business milestones, including progress in obesity and Duchenne muscular dystrophy programs, a major collaboration with GSK, and a successful $402.5 million equity financing that resulted in $602.1 million in cash and cash equivalents by year-end 2025. Executive compensation, supported by over 99% shareholder approval, includes performance-based cash bonuses, multi-year option, and RSU grants, aligning executive interests with long-term shareholder value creation.
WVE Maintained by Canaccord Genuity -- Price Target Lowered to $43.00
Canaccord Genuity has re-affirmed its 'Buy' rating on WAVE Life Sciences (WVE) but reduced its price target from $52.00 to $43.00, a 17.31% drop. Despite this, insider activity shows substantial buying, with $54.7 million in purchases versus $0.8 million in sales over the last three months. GuruFocus's GF Value™ indicates that WVE is 51.5% overvalued at its current price of $7.06 compared to its intrinsic value of $4.66.
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $43
This article provides an overview of recent analyst ratings for Wave Life Sciences (WVE.US), highlighting a price target forecast ranging from $15 to $43. The report likely details the latest adjustments to analyst recommendations and their rationale.
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Advancements
WAVE Life Sciences Ltd (WVE) reported a significant revenue increase to $38.2 million in Q1 2026, driven by advancements in its RNA programs, particularly WVE-007 for obesity and WVE-006 for AATD. Despite a net loss, the company is well-capitalized with $544.6 million, funding operations into Q3 2028, and is focused on leveraging proprietary chemistry to address competitive and regulatory challenges. CEO Paul Bolno detailed strategies for trial optimization, regulatory discussions, and differentiating their RNA editing approach in the competitive landscape.
Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)?
Wave Life Sciences (WVE) reported stronger-than-expected Q1 2026 results, with revenue up to US$38.25 million and a narrower net loss of US$26.09 million. This improved financial performance, coupled with an extended cash runway into Q3 2028, supports the company's near-term investment narrative as it progresses its RNA pipeline and obesity/AATD programs. However, the long-term success hinges on favorable data from upcoming WVE 006 and WVE 007 trials.
Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)?
Wave Life Sciences (WVE) reported stronger-than-expected Q1 2026 results, with revenue rising to US$38.25 million and net loss narrowing to US$26.09 million. This improved performance, coupled with an extended cash runway into Q3 2028, provides more time for their RNA pipeline, including obesity and AATD programs, to advance. However, the long-term investment case still hinges on the success of upcoming WVE 006 and WVE 007 trial data.
WAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What Happened
WAVE Life Sciences (NASDAQ:WVE) shares dropped 7.6% on Wednesday to $6.946, despite the company beating quarterly estimates with EPS of ($0.13) versus an expected ($0.34) and revenue of $38.25M against an $8.45M consensus. Analyst sentiment remains largely positive with 14 Buy ratings and a consensus target of $28.44, though some insiders have recently sold shares. Institutional ownership is high at 89.73%, with major new positions from firms like GSK, Adage, and Price T. Rowe.
Wave Life Sciences (Nasdaq: WVE) Q1 2026 results highlight $544.6M cash runway
Wave Life Sciences reported strong financial performance in Q1 2026, with revenue increasing to $38.2 million and a narrowed net loss of $26.1 million. The company announced a robust cash position of $544.6 million, projected to fund operations into Q3 2028, and provided key pipeline updates for its obesity, AATD, liver disease, and Duchenne muscular dystrophy programs, highlighting anticipated data readouts and regulatory milestones in 2026.
WAVE Life Sciences Q1 2026 Earnings Call Transcript
WAVE Life Sciences reported strong Q1 2026 results with revenue of $38.2 million and a narrowed net loss of $26.1 million, ending the quarter with $544.6 million in cash, expected to fund operations into Q3 2028. The company is accelerating development of WVE-007 for obesity into Phase II-A, showing durable Activin E suppression and visceral fat reduction, and advancing WVE-006 for AATD, with regulatory feedback on accelerated approval expected mid-2026. WAVE is also progressing WVE-008 for PNPLA3 liver disease towards clinical studies in 2026, leveraging its proprietary RNA chemistry and human genetic insights.
Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns
Wave Life Sciences (WVE) reported a Q1 2026 revenue of US$38.2 million, a significant increase from Q1 2025's US$9.2 million, though still incurring a basic EPS loss of US$0.13. Despite the revenue surge, the company continues to face profitability concerns with trailing twelve-month losses, leading to a mixed outlook from analysts. While bulls point to narrowing losses and potential clinical upside, bears highlight persistent losses and a high P/S ratio compared to the industry.
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences (Nasdaq: WVE) announced its first quarter 2026 financial results, highlighting significant progress in its RNA medicines pipeline. Key updates include the FDA's acceptance of the Phase 2a INLIGHT trial for WVE-007 (obesity), the upcoming presentation of RestorAATion-2 trial data for WVE-006 (AATD), and the planned CTA submission for WVE-008 (PNPLA3 I148M liver disease). The company reported $544.6 million in cash and cash equivalents, providing a cash runway into Q3 2028.
Wave Life Sciences (NasdaqGM:WVE) Stock Forecast & Analyst Predictions
Wave Life Sciences (WVE) is forecast to grow earnings by 4.2% and revenue by 45.9% annually, though it is expected to remain unprofitable for the next three years. Analyst opinions are mixed, with concerns about obesity and GLP-1 competitiveness balanced by optimism regarding clinical catalysts and pipeline progress in areas like Alpha-1 Antitrypsin Deficiency (AATD) and other genetic medicines. The company has seen recent updates in price targets and revenue estimates, reflecting both positive clinical data and market competitiveness.
Wave says obesity drug trial is on track for 2Q after FDA acceptance
Wave Life Sciences reported Q1 2026 financial results with $38.2 million in revenue and a cash runway into Q3 2028. The company announced FDA acceptance for the Phase 2a multidose INLIGHT trial of WVE-007 for obesity, expected to start in Q2 2026. Additionally, key clinical data for WVE-006 in AATD will be presented in May 2026, and Wave expects regulatory feedback on a potential accelerated approval pathway for WVE-006 by mid-2026.
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences has announced its first-quarter 2026 financial results and provided a business update. The company is advancing several RNA-based therapies, including WVE-007 for obesity, WVE-006 for AATD, and WVE-008 for PNPLA3 I148M liver disease, with multiple trials and regulatory milestones expected in 2026. Wave Life Sciences reported a net loss of $26.1 million for the quarter, with cash and cash equivalents of $544.6 million, providing a cash runway into Q3 2028.
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast
Wave Life Sciences (WVE) reported Q1 2026 earnings, significantly exceeding EPS and revenue forecasts, which led to a 3.29% rise in pre-market trading. The company's revenue surged by 315% year-over-year, and its net loss improved by 44.3% compared to Q1 2025, driven by regaining rights to WVE-006 and a collaboration with GSK. Wave Life Sciences is advancing clinical programs for obesity (WVE-007) and alpha-1 antitrypsin deficiency (WVE-006), with strong cash reserves expected to fund operations into Q3 2028.
